Mebendazole — University of Michigan (case report)
-
C Dobrosotskaya et al., 2011 — metastatic adrenal cortical cancerMebendazole monotherapy and long-term disease control in metastatic adrenocortical carcinoma. Endocrine Practice. 2011.
Patient after mitotane, 5-FU, streptozotocin, bevacizumab etc. failed. MBZ 100 mg × 2/day monotherapy: liver metastases regressed initially; disease remained stable for 19 months; well tolerated.
Mebendazole — Johns Hopkins (preclinical + phase I)
-
D Bai et al., 2011 — GBM models (Baltimore)Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme.
IC50 ~0.1–0.3 µM; microtubule disruption; mean survival extended up to ~63% in orthotopic mouse models.
-
B Gallia et al., 2021 — phase I newly diagnosed HGG + TMZNCT01729260. n=24; doses to 200 mg/kg/day. Median OS 21 months; 41.7% alive at 2 years (phase I — not designed as efficacy trial).
-
R Pediatric US registriesNCT01837862 · NCT02644291
Ivermectin — US clinical programs
-
R + B Cedars-Sinai / NCT05318469 + ASCO 2025IVM + balstilimab/pembrolizumab in metastatic TNBC. Interim ASCO 2025: safe; 1 PR, 1 SD, 6 PD; median PFS 2.5 mo.
-
R University of Florida — ICONIC (NCT07487805)IVM + immune checkpoint inhibition — planned/randomized phase II (~80 patients, 200 vs 400 µg/kg).
-
D Draganov et al., 2021 — “cold tumors hot”Ivermectin converts cold tumors hot and synergizes with immune checkpoint blockade… npj Breast Cancer.
Fenbendazole — US patient stories & series
-
C Joe Tippens protocol (US patient narrative)Well-known US narrative on small-cell lung cancer; concurrent immunotherapy confounds causality. ACS describes the case and confounders.
-
C Makis et al. — self-administration case series
Real-world / observation (IVM + MBZ)
-
B Hulscher et al., 2026High self-reported clinical benefit and tolerability in a prospective observational cohort.
American data were previously scattered; this page collects them. For other countries: World. Full table: Studies.